Davey R T, Masur H
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Antimicrob Agents Chemother. 1990 Apr;34(4):499-504. doi: 10.1128/AAC.34.4.499.
In summary, recent advances in our ability to diagnose, treat, and prevent recurrences of pneumocystis pneumonia have significantly improved the clinical management of this infection, especially in HIV-1-infected individuals. As current investigations allow our therapeutic armamentarium in this disease to be strengthened even further, it is likely that pneumocystis pneumonia will pose a diminishing threat to those patients currently most susceptible to this infection.
总之,我们在诊断、治疗和预防肺孢子菌肺炎复发方面的能力取得了最新进展,显著改善了这种感染的临床管理,尤其是在感染HIV-1的个体中。随着目前的研究使我们针对这种疾病的治疗手段得到进一步加强,肺孢子菌肺炎对目前最易感染这种疾病的患者构成的威胁可能会越来越小。